Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
Central Drug Research Institute investigators have synthesized novel compounds conjugating the quinoline moiety with a piperazine/pyrrolidine scaffold through a molecular hybridization approach and investigated their antileishmanial activity.
Researchers from Weifang Medical University and affiliated organizations have published details on the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs).
Tsinghua University has described non-structural protein 3 (nsp3; PL-pro) (SARS-CoV) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Researchers from Ipsen Ltd. and affiliated organizations presented the discovery and preclinical characterization of a novel NTCP inhibitor, A-7387, being developed for the treatment of HBV and HDV infections.
Hookipa Pharma Inc. has received clearance from the FDA for its IND application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV.
The bacterium Clostridioides difficile (C. difficile) forms organelles that help them defend against iron in the colon. According to a group of scientists from Vanderbilt University, this pathogen, which causes serious gastrointestinal infections, expresses fez genes to build structures called ferrosomes that store excess iron that is toxic to it. Its ferrosomes are surrounded by membrane and could be a target against this microorganism.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Emergex Vaccines Holding Ltd. has signed a contract with the U.K. Department of Health and Social Care (DHSC) for almost £1.8 million (US$2.2 million) to advance a CD8 T cell-based vaccine candidate against Chikungunya virus (CHIKV).
RSS
